Navigation Links
Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
Date:2/20/2008

Year-end 2007 long-term follow-up data continues to be positive

BETHESDA, Md., Feb. 20 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) ("NWBT" or the "Company") today announced the most recent long-term follow-up data, as of year-end 2007, on disease progression and overall survival in patients taking part in its Phase I and Phase I/II clinical trials for newly diagnosed patients with Glioblastoma multiforme ("GBM"), the most aggressive form of brain cancer. The additional data covers the period from April 2007 through year-end 2007. During this time, none of the patients experienced disease progression (recurrence) and only one patient died (at 36.4 months). Thus, the data show that in the 19 clinical trial patients receiving DCVax(R)-Brain in addition to Standard of Care, both the median overall survival and the median time to disease progression (recurrence) are more than twice as long as in patients receiving the Standard of Care for GBM. Dr. Linda Liau, Associate Professor of Neurosurgery and Director of the Malignant Brain Tumor Program at the UCLA School of Medicine ("UCLA"), served as the Principal Investigator for the trial.

Since 2005, the Standard of Care for patients with GBM is surgery followed by a combination of radiation and daily Temodar(R) chemotherapy, and then 6 monthly cycles of Temodar chemotherapy. The studies defining this Standard of Care achieved a median time to progression of 6.9 months and a median overall survival of 14.6 months (Stupp, et. al., N Engl J Med, 352:987, 2005). Further data from UCLA have demonstrated a somewhat longer median time to progression of 8.1 months and median overall survival of 17.0 months in patients with GBM who received Standard of Care.

The year-end 2007 data obtained by the Company concerning the 19 patients from the two trials at UCLA with newly diagnosed GBM continue to be positive, with no patients progressing and onl
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ) today ... James H. Mackaness is scheduled to present at the ... am PT in Los Angeles . ... accessed on the Event Calendar of the Investors section of ... webcast will be available shortly after the conclusion of the ...
(Date:5/28/2015)... 2015 Research and Markets ... the "United States Medical Adhesives Market Forecast ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , , ... the United States is projected to ... Medical device manufacturers across the US are expanding ...
(Date:5/28/2015)... The Parenteral Drug Association (PDA) proudly ... of the Johnson & Johnson Kilmer Conference on ... Johnson & Johnson (J&J) is reviving the conference ... endoscopes. J&J ran 8 conferences on sterilization, validation ... on advances in sterilization and other topics. ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3PDA Announces Support for the Johnson & Johnson Kilmer Conference 2
(Date:5/28/2015)... Park Cities Pet Sitter is offering a 5-week “Training ... Saturday, June 6th at 10:30am. The classes will be ... Dallas, with a maximum of six dogs allowed in the ... no class being held over the 4th of July weekend. ... Intermediate-to-Advanced level class, dogs will solidify their practical behavior skills, ...
(Date:5/28/2015)... May 28, 2015 New Jersey Plastic ... in delivering world-class results. With over 30 years ... a background in art, Dr. Rafizadeh knows what it ... approach to Plastic Surgery involves the principles of proportion, ... a superior level of comfort and personalized care from ...
(Date:5/28/2015)... As the summer approaches, many people will ... important to make safety a top priority, however, and that’s ... , According to the Centers for Disease Control, 10 people ... including boating incidents. Additionally, the National Safety Council says drowning ... to 4. , Amica is sharing the following tips ...
(Date:5/28/2015)... " Trends Investing ” was featured on NewsWatch as part ... small, medium, and large businesses making an impact in their ... conducted the business review and shared with viewers how this ... their money. , The idea, “let your money work for ... knowing how to succeed are two different things. So ...
(Date:5/28/2015)... 28, 2015 More than 300 locations ... raise money to help the Muscular Dystrophy Association save ... and related life-threatening diseases that limit muscle strength and ... program. , From June 1 to June 30, sweetFrog ... the opportunity to help send local children affected by ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Splash! Amica Shares 6 Swimming Safety Tips 2Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3
... 6, 2011Seven of 10 adults think the U.S. health ... rebuilt, according to a Commonwealth Fund survey released today. ... coordinated care and growing costs. The survey also reveals ... use of teams and information systems. The ...
... HealthDay Reporter , TUESDAY, April 5 (HealthDay News) -- ... indicate the severity of Alzheimer,s disease, but it doesn,t serve ... the findings are helpful because they reveal that signs of ... of the study. "What,s promising is that we can ...
... , TUESDAY, April 5 (HealthDay News) -- ... device shows promise, researchers report. The device, surgically ... six-volt electrical jolt to the carotid arteries. This is ... as baroreflex activation therapy. The researchers were scheduled ...
... HealthDay Reporter , TUESDAY, April 5 (HealthDay News) ... soy will increase the risk of a cancer recurrence, but ... "We did not see any evidence that soy intake ... [from breast cancer]," said Dr. Xiao Ou Shu, a professor ...
... treat people with resistant hypertension helped lower blood pressure by ... to take an additional three or four drugs, on top ... to control their difficult-to-treat condition. The ... Phase III study presented today as a late-breaking clinical trial ...
... -- Thanks to the zebrafish, there is new hope for people ... 8,700 deaths each year in the United States. In a ... journal Nature , and featured on the cover, researchers identified ... and may play a role in up to 70 percent of ...
Cached Medicine News:Health News:New survey: 72 percent of Americans think health-care system needs major overhaul 2Health News:New survey: 72 percent of Americans think health-care system needs major overhaul 3Health News:Blood Marker Suggests Severity of Alzheimer's Disease 2Health News:Blood Marker Suggests Severity of Alzheimer's Disease 3Health News:Implantable Device May Lower Tough-to-Treat Hypertension 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 3Health News:Soy Foods OK After Breast Cancer: Study 2Health News:Device drops blood pressure in patients with difficult-to-treat hypertension 2Health News:Device drops blood pressure in patients with difficult-to-treat hypertension 3Health News:Researchers use zebrafish to identify new gene linked to melanoma 2Health News:Researchers use zebrafish to identify new gene linked to melanoma 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: